KR20230041758A - 보체 인자의 저해제 및 이의 용도 - Google Patents

보체 인자의 저해제 및 이의 용도 Download PDF

Info

Publication number
KR20230041758A
KR20230041758A KR1020237005805A KR20237005805A KR20230041758A KR 20230041758 A KR20230041758 A KR 20230041758A KR 1020237005805 A KR1020237005805 A KR 1020237005805A KR 20237005805 A KR20237005805 A KR 20237005805A KR 20230041758 A KR20230041758 A KR 20230041758A
Authority
KR
South Korea
Prior art keywords
compound
disease
mmol
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005805A
Other languages
English (en)
Korean (ko)
Inventor
딘 알. 아티스
콜린 필립 레슬리
루카 비아지오 마일리오
클라우디아 비에토
페데리코 소라나
굴리엘모 브루노 디
키아라 파드로니
Original Assignee
애넥슨, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애넥슨, 인코포레이티드 filed Critical 애넥슨, 인코포레이티드
Publication of KR20230041758A publication Critical patent/KR20230041758A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237005805A 2020-07-20 2021-07-19 보체 인자의 저해제 및 이의 용도 Pending KR20230041758A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063054064P 2020-07-20 2020-07-20
US63/054,064 2020-07-20
PCT/US2021/042198 WO2022020244A1 (en) 2020-07-20 2021-07-19 Inhibitors of complement factors and uses thereof

Publications (1)

Publication Number Publication Date
KR20230041758A true KR20230041758A (ko) 2023-03-24

Family

ID=79729495

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005805A Pending KR20230041758A (ko) 2020-07-20 2021-07-19 보체 인자의 저해제 및 이의 용도

Country Status (18)

Country Link
US (3) US11814404B2 (https=)
EP (1) EP4185592A4 (https=)
JP (1) JP7793595B2 (https=)
KR (1) KR20230041758A (https=)
CN (2) CN116947903A (https=)
AR (1) AR123011A1 (https=)
AU (1) AU2021311455A1 (https=)
BR (1) BR112023001007A2 (https=)
CA (1) CA3186022A1 (https=)
CL (1) CL2023000191A1 (https=)
CO (1) CO2023000683A2 (https=)
IL (1) IL299840A (https=)
MX (1) MX2023000919A (https=)
PE (1) PE20231435A1 (https=)
PH (1) PH12023550153A1 (https=)
TW (1) TW202216168A (https=)
UY (1) UY39331A (https=)
WO (1) WO2022020244A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof
IL314164A (en) 2022-01-14 2024-09-01 Annexon Inc Inhibitors of complement factors and their uses
AR131723A1 (es) * 2023-01-30 2025-04-23 5Metis Inc Compuestos que contienen boro y sus usos
WO2024254704A1 (en) * 2023-06-15 2024-12-19 The Governors Of The University Of Alberta Hemiboronic heterocyclic compounds and uses thereof
EP4553080A1 (en) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1971664B1 (en) * 2006-01-13 2015-09-09 LG Chem, Ltd. Emitting materials and organic light emitting device using the same
KR20100031723A (ko) 2007-07-07 2010-03-24 이데미쓰 고산 가부시키가이샤 크리센 유도체 및 이를 이용한 유기 전계 발광 소자
KR101233377B1 (ko) 2008-12-30 2013-02-18 제일모직주식회사 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
WO2013049332A1 (en) * 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2015003146A1 (en) * 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
TWI532741B (zh) 2013-09-04 2016-05-11 喜星素材股份有限公司 含吡唑之多環化合物及使用其之有機發光裝置
KR101635154B1 (ko) 2014-08-28 2016-06-30 (주)더블유에스 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자
KR102233296B1 (ko) * 2014-11-18 2021-03-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
US10111885B2 (en) * 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR101981245B1 (ko) 2015-10-27 2019-05-22 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
KR101806464B1 (ko) 2015-11-19 2017-12-07 (주)랩토 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자
KR102496411B1 (ko) 2016-01-06 2023-02-06 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2019240471A1 (ko) 2018-06-11 2019-12-19 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2020032428A1 (ko) * 2018-08-09 2020-02-13 덕산네오룩스 주식회사 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치
CN109574917B (zh) 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
CN109574910B (zh) * 2018-12-19 2021-07-02 山西大学 一种咔唑衍生物mcab及其制备方法和应用
CN111087387B (zh) 2019-12-26 2022-04-29 厦门天马微电子有限公司 一种有机化合物、显示面板及显示装置
CN111423390A (zh) 2020-03-30 2020-07-17 北京燕化集联光电技术有限公司 一种新型结构化合物及其应用
CN111662309B (zh) 2020-07-10 2021-11-09 北京燕化集联光电技术有限公司 一种多杂环结构化合物及其应用
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof
CN113045585A (zh) 2021-03-16 2021-06-29 吉林奥来德光电材料股份有限公司 一种有机稠环化合物及其制备方法和应用
CN113831332B (zh) 2021-10-29 2024-06-18 长春海谱润斯科技股份有限公司 一种含氮杂环衍生物及其在有机电致发光器件中的应用
IL314164A (en) 2022-01-14 2024-09-01 Annexon Inc Inhibitors of complement factors and their uses

Also Published As

Publication number Publication date
CL2023000191A1 (es) 2023-09-08
US20240109920A1 (en) 2024-04-04
UY39331A (es) 2022-02-25
AU2021311455A1 (en) 2023-02-16
CN116947903A (zh) 2023-10-27
MX2023000919A (es) 2023-04-19
CA3186022A1 (en) 2022-01-27
BR112023001007A2 (pt) 2023-03-28
IL299840A (en) 2023-03-01
PE20231435A1 (es) 2023-09-14
US11814404B2 (en) 2023-11-14
EP4185592A1 (en) 2023-05-31
CO2023000683A2 (es) 2023-01-26
AR123011A1 (es) 2022-10-19
EP4185592A4 (en) 2024-08-21
US12509474B2 (en) 2025-12-30
JP7793595B2 (ja) 2026-01-05
JP2023534974A (ja) 2023-08-15
US20220048930A1 (en) 2022-02-17
PH12023550153A1 (en) 2024-03-18
WO2022020244A1 (en) 2022-01-27
US20260070932A1 (en) 2026-03-12
TW202216168A (zh) 2022-05-01
CN116261564A (zh) 2023-06-13

Similar Documents

Publication Publication Date Title
KR20230041758A (ko) 보체 인자의 저해제 및 이의 용도
ES2729243T3 (es) Compuestos y composiciones como inhibidores de quinasa
EP4146348B1 (en) Inhibitors of nek7 kinase
AU2021237841A1 (en) Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
CN102827170A (zh) 治疗活性组合物和它们的使用方法
EP4051680B1 (en) Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
EA023775B1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
CN114450283A (zh) 3,6-二氨基-哒嗪-3-基衍生物、含有它们的药物组合物及其作为促凋亡剂的用途
JP2018525372A (ja) 呼吸器合胞体ウイルス阻害剤
WO2019205979A1 (zh) 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
KR20180094946A (ko) 알킬 다이하이드로퀴놀린 설폰아마이드 화합물
EP4232431B1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
CN113272272A (zh) Rip1抑制剂
EP3268376A1 (en) Enolase inhibitors and methods of treatment therewith
KR20240135818A (ko) 보체 인자의 저해제 및 이의 용도
FI105270B (fi) Menetelmä terapeuttisesti käyttökelpoisten oktahydro-1H-1-pyrindiini-4,5,6,7-terolien valmistamiseksi
CN118165034A (zh) 核苷酸类化合物及其组合物及用途
CA3259338A1 (en) ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TWI810547B (zh) Pd-l1拮抗劑化合物
WO2026073439A1 (en) Vps4 inhibitors and methods of use thereof
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
HK40096479A (zh) 补体因子的抑制剂和其用途
CN119343143A (zh) 含硼嘧啶化合物、包含它们的组合物、其方法和用途
WO2017198159A1 (zh) 含桥环的咪唑衍生物
CN118994004A (zh) (+)-sclerotiorin衍生物在抗分枝杆菌药物的应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902